API2-MALT1 fusion protein seems to trigger cancer What happens when two proteins join jointly?

Both kinases and proteases are believed druggable, meaning they are potential targets for developing medicines that block their activity, says Lucas, assistant professor of pathology at the U-M Medical College. MALT lymphomas that carry the API2-MALT1 fusion proteins tend to be aggressive and even more resistant to treatment. The effect is bigger tumors and improved spread through the entire body. The researchers found that once NIK turns into stable, it triggers a number of downstream reactions that produce cells more likely to metastasize and even more resistant to current treatments.Physicians make an effort to achieve an international normalized ratio of 2-3, which is within the therapeutic range, or the basic safety range. Typically, dosages greater than the therapeutic range can raise the risk of bleeding. If the dose is lower than the therapeutic range, it can increase risk of blood clots forming. Three years ago researchers at the Intermountain INFIRMARY Heart Institute found that patients with atrial fibrillation had been at higher risk for developing dementia, but the cause of that association – the hyperlink between anticoagulation medicine and dementia – was unknown.